DENVER - Palisade Bio, Inc. (NASDAQ:PALI) announced today the appointment of Robert Baltera and Jordan Zwick to its Board of Directors, according to a press release statement.
Baltera is a Senior Advisor at Frazier Life Sciences with over 30 years of biopharmaceutical experience. He previously served as Chief Executive Officer of Amira Pharmaceuticals prior to its sale to Bristol-Myers Squibb in 2011 for $475 million. He has held board positions at several companies, including Imago BioSciences, which was acquired by Merck, and currently serves on the Board of Directors of Inipharm. Baltera spent 17 years at Amgen in various senior management roles.
Zwick is Co-Founder and Chief Business Officer of Mirador Therapeutics. He served as a strategic advisor to Prometheus Biosciences before its acquisition by Merck in 2023 and to CrossBridge Bio through its acquisition by Eli Lilly in 2026. He was a Board member of Theratechnologies, Inc. prior to its sale to Future Pak in 2025. Zwick previously held senior positions at Amarin Corporation and InflaRx N.V.
Palisade Bio is a clinical-stage biopharmaceutical company developing oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. The company’s lead program, PALI-2108, is designed for targeted delivery to the terminal ileum and colon. The drug candidate has completed a Phase 1a trial and two Phase 1b clinical trials, including studies in ulcerative colitis and fibrostenotic Crohn’s disease. The company is advancing toward Phase 2 clinical studies.The company, with a market capitalization of $281 million, maintains a strong balance sheet with more cash than debt and liquid assets that exceed short-term obligations by a significant margin. Despite a 13% decline over the past week and a 29% drop year-to-date, the stock has delivered a remarkable 156% return over the past year. According to InvestingPro analysis, which offers access to over 10 additional exclusive tips and comprehensive financial metrics, the stock currently appears overvalued relative to its Fair Value.
JD Finley, Chief Executive Officer of Palisade Bio, stated the appointments will provide expertise in biotechnology company building, strategic transactions, capital markets and operational execution as the company advances PALI-2108 through clinical development.
In other recent news, Palisade Bio Inc. presented additional Phase 1a/b data for its ulcerative colitis treatment, PALI-2108, at Digestive Disease Week 2026. The analyses revealed that the active metabolite PALI-0008 achieved steady-state concentrations within 48 hours, with tissue-to-plasma exposure ratios approximately six-fold. Additionally, Palisade Bio announced a master services agreement with Iterative Health to support patient enrollment for a Phase 2 study of PALI-2108. The company also completed a $3 million stock sale to an affiliate of Iterative Health. Piper Sandler reiterated an Overweight rating for Palisade Bio, maintaining a $25.00 price target, following positive Phase 1b data. Clear Street also reiterated a Buy rating with a $12.00 price target, citing the Phase 1b results as validation for PALI-2108. Palisade Bio’s data from the PALI-2108 program was selected for presentation at Digestive Disease Week 2026, highlighting its potential in treating ulcerative colitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates PALI alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if PALI is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?